Dr. Daniel W. Sherbenou, MD, PHD
Hematology & Oncology (Hematology & Oncology Physician)
1665 Aurora Ct, 1665 Aurora Court Mail Stop F754
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Oregon Health Sciences University School of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 211
Licensed in Colorado since 2011, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Oregon Health Sciences University School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license DR.0055891 (first issued 2015; active) -
Hematology (Internal Medicine) Physician
CO license DR.0055891 (first issued 2015; active) -
Hepatology Physician
CO license 0050375 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Uch-Memorial Health System Colorado Springs, CO
- Uchealth Highlands Ranch Hospital Highlands Ranch, CO
- Longs Peak Hospital Longmont, CO
- Uchealth Broomfield Hospital Broomfield, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 211
- Services billed
- 504
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 204 | 79 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 183 | 37 |
| Hospital discharge day management, 30 minutes or less | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Aurora, CO | 193 |
| Lenalidomide | 162 |
| Revlimid (lenalidomide) | 152 |
| Pomalyst (pomalidomide) | 73 |
| Oxycodone Hcl Other prescribers in Aurora, CO | 28 |
| Potassium Chloride Other prescribers in Aurora, CO | 27 |
| Trazodone Hcl Other prescribers in Aurora, CO | 26 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Aurora, CO | 23 |
| Lorazepam Other prescribers in Aurora, CO | 23 |
| Dexamethasone Other prescribers in Aurora, CO | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $1,545 in total to this clinician.
| Janssen Biotech, Inc. | $1,320 |
|---|---|
| Genzyme Corporation | $146 |
| AbbVie Inc. | $71.28 |
| Janssen Scientific Affairs, LLC | $7.29 |
| Consulting Fee | $1,170 |
|---|---|
| Food and Beverage | $375 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 5, 2025 | Consulting Fee | $1,170 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $112,720 in research payments for these studies, mostly to the institutions running them.
- Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients
Genentech, Inc. - Ph I of FcRH5 CD3 in multiple myeloma
Genentech, Inc. - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amylo…
Janssen Research & Development, LLC - A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.